TrialAnnals of the rheumatic diseases2014

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.

Bernard Combe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.